134526-69-5

Basic information

• Product Name: (R)-2-FORMYL-PIPERIDINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER
• Synonyms: (R)-2-FORMYL-PIPERIDINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER;2R-FORMYL-PIPERIDINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER;1-PIPERIDINECARBOXYLIC ACID, 2-FORMYL-, 1,1-DIMETHYLETHYL ESTER, (R);(R)-1-Boc-2-piperidinecarboxaldehyde;(R)-2-Formyl-1-piperidinecarboxylic acid tert-butyl ester;1-Piperidinecarboxylic acid, 2-formyl-, 1,1-dimethylethyl ester, (2R)-;tert-butyl (2R)-2-forMylpiperidine-1-carboxylate;tert-Butyl (3R)-3-formylmorpholine-4-carboxylate
• CAS NO: 134526-69-5
• Molecular Formula: C₁₁H₁₉NO₃
• Molecular Weight: 213.27
• Mol File: 134526-69-5.mol

Chemical Properties

• Boiling Point: 295.431 °C at 760 mmHg
• Flash Point: 132.472 °C
• Appearance: /
• Density: 1.115 g/cm³
• Vapor Pressure: 0.002mmHg at 25°C
• Refractive Index: 1.519
• Storage Temp.: 2-8°C
• CAS DataBase Reference: (R)-2-FORMYL-PIPERIDINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: (R)-2-FORMYL-PIPERIDINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER(134526-69-5)
• EPA Substance Registry System: (R)-2-FORMYL-PIPERIDINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER(134526-69-5)

Safety Data

• Hazardous Substances Data: 134526-69-5(Hazardous Substances Data)

Usage

Uses

Used in Organic Chemistry:
(R)-2-FORMYL-PIPERIDINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER is used as a building block for the synthesis of various pharmaceuticals and other complex organic molecules. Its unique structure allows for the creation of a wide range of compounds with diverse applications in the pharmaceutical industry.
Used in Chemical Research and Development:
In the realm of chemical research and development, (R)-2-FORMYL-PIPERIDINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER serves as a valuable reagent. Its properties make it suitable for use in various chemical reactions and processes, contributing to the advancement of scientific knowledge and the development of new chemical products.
Used in Pharmaceutical Industry:
(R)-2-FORMYL-PIPERIDINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER is used as a key intermediate in the synthesis of pharmaceutical compounds. Its versatility and reactivity enable the production of a variety of drug candidates, potentially leading to the discovery of new treatments and therapies for various medical conditions.
Used in Laboratory Settings:
Due to the tert-butyl ester group, (R)-2-FORMYL-PIPERIDINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER is used for its increased stability and ease of handling in laboratory settings. This makes it a preferred choice for researchers and chemists working with sensitive or reactive compounds, ensuring safer and more efficient experimental procedures.

InChI:InChI=1/C11H19NO3/c1-11(2,3)15-10(14)12-7-5-4-6-9(12)8-13/h8-9H,4-7H2,1-3H3

Upstream product

• 75844-69-8 t-butyl piperidinecarboxylate 
• 68-12-2 N,N-dimethyl-formamide 
• 1073314-61-0 tert-butyl N-allyl-N-(1R)-1-[(4S)-2,2-dimethyl-1,3-dioxolan-4-yl]-3-butenylcarbamate 
• 1268624-34-5 (R)-tert-butyl 6-((S)-2,2-dimethyl-1,3-dioxolan-4-yl)-5,6-dihydropyridine-1(2H)-carboxylate 
• 1268624-35-6 (R)-tert-butyl 2-((S)-2,2-dimethyl-1,3-dioxolan-4-yl)piperidine-1-carboxylate 
• 1013212-42-4 tert-butyl 1-(R)-2-((S)-1,2-dihydroxylethyl)piperidine-1-carboxylate 
• 35677-83-9 (+)-2R-Piperidine-2-carboxylic acid methyl ester 
• 24424-99-5 di-tert-butyl dicarbonate 
• 1723-00-8 (R)-(+)-pipecolic acid 
• 3197-44-2 (2R)-piperidin-2-ylmethanol 
• 28697-17-8 N-BOC-D-pipecolic acid 
• 164456-75-1 1-(R)-tert-butyl 2-methyl piperidine-1,2-dicarboxylate 
• 203056-15-9 tert-butyl (2R)-2-[methoxy(methyl)carbamoyl]piperidine-1-carboxylate 
• 134441-61-5 tert-butyl (2R)-2-(hydroxymethyl)piperidine-1-carboxylate 

Downstream Products

• 125279-72-3 (1R,2R,8aR)-lentiginosine 
• 160169-49-3 (1R,2S,8aR)-1,2-dihydroxy-hexahydroindolizin-3(5H)-one 
• 134441-61-5 tert-butyl (2R)-2-(hydroxymethyl)piperidine-1-carboxylate 
• 138775-33-4 Fmoc-D-Phe-L-Ile-D-Pip-L-Pip-D-(N-allyl)Phe-L-Pro-OCH₂Ph 
• 144073-33-6 Fmoc-L-Ile-D-Pip-L-Pip-D-(N-allyl)Phe-L-Pro-OCH₂Ph 
• 1026159-93-2 D-Pip-L-Pip-D-(N-allyl)Phe-L-Pro-OCH₂Ph 
• 220384-49-6 (2R)-2-vinylpiperidine-1-carboxylic acid tert-butyl ester 
• 1094503-62-4 tert-butyl (2R)-2-[(R)-(3-chloro-5-fluorophenyl)(hydroxy)methyl]piperidine-1-carboxylate 
• 1094503-59-9 tert-butyl (2R)-2-[(S)-(3-chloro-5-fluorophenyl)(hydroxy)methyl]piperidine-1-carboxylate 

Relevant articles and documents

X-ray Structure-Guided Discovery of a Potent, Orally Bioavailable, Dual Human Indoleamine/Tryptophan 2,3-Dioxygenase (hIDO/hTDO) Inhibitor That Shows Activity in a Mouse Model of Parkinson’s Disease

Human indoleamine 2,3-dioxygenase 1 (hIDO1) and tryptophan 2,3-dioxygenase (hTDO) have been closely linked to the pathogenesis of Parkinson’s disease (PD); nevertheless, development of dual hIDO1 and hTDO inhibitors to evaluate their potential efficacy against PD is still lacking. Here, we report biochemical, biophysical, and computational analyses revealing that 1H-indazole-4-amines inhibit both hIDO1 and hTDO by a mechanism involving direct coordination with the heme ferrous and ferric states. Crystal structure-guided optimization led to23, which manifested IC50values of 0.64 and 0.04 μM to hIDO1 and hTDO, respectively, and had good pharmacokinetic properties and brain penetration in mice.23showed efficacy against the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced mouse motor coordination deficits, comparable to Madopar, an anti-PD medicine. Further studies revealed that different from Madopar,23likely has specific anti-PD mechanisms involving lowering IDO1 expression, alleviating dopaminergic neurodegeneration, reducing inflammatory cytokines and quinolinic acid in mouse brain, and increasing kynurenic acid in mouse blood.

Compound, preparation method thereof, pharmaceutical composition and application of compound

The invention discloses a compound, a preparation method thereof, a pharmaceutical composition and application of the compound. The compound I, and a stereoisomer or a pharmacologically acceptable salt thereof can serve as a CDK7 kinase inhibitor, are high in inhibition activity, and can be used for treatment of various malignant tumors.

COMPOUNDS AND USE FOR TREATING CANCER

The present invention relates to certain 2,4-disubstituted quinoline derivatives, to their therapy, as well as to pharmaceutical compositions comprising said compounds. More specifically the invention relates to certain 2,4-disubstituted quinoline derivatives or pharmaceutical compositions comprising said compounds for the treatment of cancers characterized by overactive Ras and/or Rac or signalling pathway.

Benzimidazole-2-piperazine compound, its pharmaceutical composition and its preparation and use

The invention relates to a benzimidazole-2-piperazine derivative and a preparing method and application of the benzimidazole-2-piperazine derivative in medicine, in particular to a novel benzimidazole-2-piperazine derivative shown in the general formula (I), a preparing method of the derivative, a pharmaceutical composition containing the derivative and application of the derivative serving as a therapeutic agent, especially serving as a poly (ADP-ribose) polymerase (PARP) inhibitor. In the general formula (I), R refers to hydrogen or halogen, G refers to carbonyl or methylene, m is 1-2, n is 1-3, and Q refers to hydrogen or C1-C4 alkyl. When X is methylene and Y is NR1 or methylene, X is NR1; R1 refers to hydrogen, C1-C6 alkyl, benzyl, COR2 or SO2R2; R2 refers to the following groups which are not substituted or groups substituted by 1-3 substituent groups, including C1-C6 alkyl, C3-C8 naphthenic base, phenyl, benzyl, naphthyl and C5-C10 aromatic heterocycle base, heterocycle in the C5-C10 aromatic heterocycle base comprises 1-3 heteroatoms selected from N, O and S, and the substituent groups are selected from the following atoms or groups of C1-C6 alkyl, C1-C6 alkoxy, halogen, amidogen, nitryl, sulfydryl, hydroxyl, cyanogroup and trifluoromethyl. The general formula (I) is shown in the specification.

SUBSTITUTED ADIPIC ACID AMIDES AND USES THEREOF

The present invention provides compounds of Formula (I), or a pharmaceutically acceptable salt thereof, wherein A is a five to eight membered monocyclic or a nine to twelve membered bicyclic heterocyclic ring, as further defined herein; Y is S, CH2, or CH; Z is CH or N; R7 and R9 are hydrogen or (C1-C6)alkyl; R2 is (C1 C6)alkoxy, OH, CN, (C1-C6)alkyl, halogen, or CF3; r and s are 0, 1, or 2; and R1 and R3 are as further defined herein. These compounds are agonists, partial agonists and/or modulators of the NPY4 receptor and may be used for the treatment and prophylaxis of obesity, food intake, and other diseases and conditions modulated by the NPY4 receptor.

An expedient total synthesis of optically active piperidine and indolizidine alkaloids (-)-β-conhydrine and (-)-lentiginosine

Attempts directed toward the stereocontroled total synthesis of piperidine and indolizidine alkaloids resulted in the synthesis of (-)-β-conhydrine 1 and (-)-lentiginosine 3. The synthesis of 1 and 3 were developed from protected d-mannitol as the chiral

Dynamic resolution of N-Boc-2-lithiopiperidine

Dynamic thermodynamic resolution of N-Boc-2-lithiopiperidine is possible using a chiral ligand; the two enantiomers of this organolithium can be resolved with selectivities of up to 85: 15 from a selection of 26 chiral diamino-alkoxide ligands screened. The Royal Society of Chemistry.

TETRAZOLE DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS

The present invention relates to new compounds of formula (I) wherein Y1 and Y2 selected from the group consisting of hydrogen, halogen atom, C1-4 alkyl, C1-4 alkoxy or cyano group, X is oxygen or two hydrogen a

MGLUR5 MODULATORS II

The present invention is directed to novel compounds, to a process for their preparation, their use in therapy and pharmaceutical compositions comprising the novel compounds.

MGluR5 modulators I

The present invention is directed to novel compounds, to a process for their preparation, their use in therapy and pharmaceutical compositions comprising the novel compounds.